Hainan Haiyao Co., Ltd.

000566

CNE0000004W8

HAINAN HAIYAO CO., LTD. is a China-based company principally engaged in the research, development, manufacture and sale of medicines and medical instrument. The Companyâs main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The Company distributes its products in domestic market and to overseas market, with China as its main market.

Employees

2,108

Sector

Pharmaceuticals

Calendar

24/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 09/09/2024			5-day change	1st Jan Change
3.710 ^CNY	+10.09%		+24.08%	-17.92%

08-29	Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
08-14	Hainan Haiyao Vice Chair Resigns	MT

Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-29	CI
Hainan Haiyao Vice Chair Resigns	08-14	MT
China Shares Rise On Upcoming Economic Data; Hainan Haiyao Soars 10%	08-13	MT
Hainan Haiyao Gets Commercialization Rights for Pharmathen's Schizophrenia Drug; Shares Up 10%	08-13	MT
New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	07-09	MT
AFT Pharmaceuticals to Launch Skin Infection Cream in China	07-08	MT
AFT Pharmaceuticals Announces an Agreement with Hainan Haiyao Co. Ltd to Distribute Crystaderm® Cream in China	07-08	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Hainan Haiyao’s Antibiotic Passes Generic Evaluation	01-31	MT
Hainan Haiyao's Unit Gets Nod to Become Marketing License Holder of Shuangshen Huoxue Tongluo Granules	12-08	MT
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
China Sanctions Hainan Haiyao, Former Vice Chairman Over Information Disclosure Violations	05/10/23	MT
Hainan Haiyao Co., Ltd.(XSEC:000566) added to S&P Global BMI Index	18/09/23	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Hainan Haiyao Unit Receives 1.2 Million Yuan Government Subsidy	21/08/23	MT
Hainan Haiyao Co., Ltd. Announces Management Changes	01/06/23	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/04/23	CI
Hainan Haiyao Unit's Minocycline Hydrochloride Capsules Passes Drug Regulator's Evaluation	08/03/23	MT
Hainan Haiyao Unit Gets Regulatory Nod for Antibacterial Drug	31/01/23	MT
Hainan Haiyao Gets Regulatory Nod for Anti-Skin Disease Drug	09/01/23	MT
Xinxing Cathay International Capital Holdings Limited agreed completed the acquisition of 43% stake in Shanghai Listent Medical Tech Co., Ltd. from Hainan Haiyao Co., Ltd.	06/01/23	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Xinxing Cathay International Capital Holdings Limited agreed to acquire a 43% stake in Shanghai Listent Medical Tech Co., Ltd. from Hainan Haiyao Co., Ltd. for approximately CNY 240 million.	20/10/22	CI

Hainan Haiyao Co., Ltd.

Equities

000566

CNE0000004W8

Pharmaceuticals

Latest news about Hainan Haiyao Co., Ltd.

Chart Hainan Haiyao Co., Ltd.

Company Profile

Income Statement and Estimates